Capricor Therapeutics (CAPR) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 8.0% versus a loss of 57.8%. Over five years, CAPR leads with a +104.5% price change compared with -55.8% for SPRY. Capricor Therapeutics is the larger company by market cap ($470.9 million vs $433.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | SPRY |
|---|---|---|
| Share price | $8.10 | $4.36 |
| Market cap | $470.93M | $433.59M |
| 1-day change | +4.52% | +1.51% |
| YTD return | -71.93% | -62.58% |
| 1-year return | +8.00% | -57.79% |
| 5-year return | +104.55% | -55.78% |
| EPS (TTM) | $-2.45 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.37 | $13.15 |
| 52-week low | $2.96 | $3.99 |
| Distance from 52-week high | -79.94% | -66.84% |
| Analyst consensus | buy | none |
| Avg. price target upside | +233.33% | +416.06% |
| Average volume | 6.83M | 1.86M |
| Shares outstanding | 58.14M | 99.45M |
| Employees | 231 | 195 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed SPRY by 65.8 percentage points over the past year.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Healthcare · Biotechnology · 231 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Healthcare · Biotechnology · 195 employees
CAPR vs SPRY FAQ
Which is bigger, Capricor Therapeutics or ARS Pharmaceuticals?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $470.93M compared with $433.59M for ARS Pharmaceuticals (SPRY).
Which stock has performed better over the past year, CAPR or SPRY?
CAPR returned +8.00% over the past 12 months, compared with -57.79% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.